NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Ocugen, Inc. (NASDAQ:OCGN)
CONTACT JAKUBOWITZ ABOUT OCGN:
https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=18226&from=1
Class Period : February 2, 2021 - June 10, 2021
Lead Plaintiff Deadline : August 17, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Athira Pharma, Inc. (NASDAQ:ATHA)
CONTACT JAKUBOWITZ ABOUT ATHA:
https://claimyourloss.com/securities/athira-pharma-inc-loss-submission-form/?id=18226&from=1
This lawsuit is on behalf of investors who purchased Athira Pharma, Inc. (NASDAQ: ATHA) between September 18, 2020 and June 17, 2021 and/or purchased common stock in or traceable to the Company's registration statement issued in connection with the Company's September 2020 initial public offering priced at $17.00 per share.
Lead Plaintiff Deadline : August 24, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the research conducted by Defendant Kawas, which formed the foundation for Athira's product candidates and intellectual property, was tainted by Kawas' scientific misconduct, including the manipulation of key data through the altering of Western blot images; and (2) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and omitted material facts necessary in order to make the statements made not misleading.
CorMedix Inc. (NASDAQ:CRMD)
CONTACT JAKUBOWITZ ABOUT CRMD:
https://claimyourloss.com/securities/cormedix-inc-loss-submission-form/?id=18226&from=1
Class Period : July 8, 2020 - May 13, 2021
Lead Plaintiff Deadline : September 20, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/658376/LAWSUITS-FILED-AGAINST-OCGN-ATHA-and-CRMD--Jakubowitz-Law-Pursues-Shareholders-Claims
